DD146049A5 - Verfahren zur herstellung von komplexverbindungen von 9-hydroxyalkyl-purinen - Google Patents

Verfahren zur herstellung von komplexverbindungen von 9-hydroxyalkyl-purinen Download PDF

Info

Publication number
DD146049A5
DD146049A5 DD79215495A DD21549579A DD146049A5 DD 146049 A5 DD146049 A5 DD 146049A5 DD 79215495 A DD79215495 A DD 79215495A DD 21549579 A DD21549579 A DD 21549579A DD 146049 A5 DD146049 A5 DD 146049A5
Authority
DD
German Democratic Republic
Prior art keywords
group
dip
pacba
acid
introduce
Prior art date
Application number
DD79215495A
Other languages
German (de)
English (en)
Inventor
Lionel N Simon
John W Hadden
Original Assignee
Newport Pharmaceuticals
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newport Pharmaceuticals, Sloan Kettering Inst Cancer filed Critical Newport Pharmaceuticals
Publication of DD146049A5 publication Critical patent/DD146049A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DD79215495A 1978-09-15 1979-09-12 Verfahren zur herstellung von komplexverbindungen von 9-hydroxyalkyl-purinen DD146049A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/942,802 US4221909A (en) 1978-09-15 1978-09-15 P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines

Publications (1)

Publication Number Publication Date
DD146049A5 true DD146049A5 (de) 1981-01-21

Family

ID=25478620

Family Applications (1)

Application Number Title Priority Date Filing Date
DD79215495A DD146049A5 (de) 1978-09-15 1979-09-12 Verfahren zur herstellung von komplexverbindungen von 9-hydroxyalkyl-purinen

Country Status (27)

Country Link
US (1) US4221909A (xx)
EP (1) EP0009154B1 (xx)
JP (1) JPS5547683A (xx)
KR (1) KR840000552A (xx)
AT (1) ATE1949T1 (xx)
AU (1) AU527851B2 (xx)
CA (1) CA1122217A (xx)
CS (1) CS251060B2 (xx)
DD (1) DD146049A5 (xx)
DE (1) DE2964211D1 (xx)
DK (1) DK149857C (xx)
ES (1) ES484167A1 (xx)
FI (1) FI68234C (xx)
GR (1) GR74076B (xx)
HU (1) HU182544B (xx)
IE (1) IE48827B1 (xx)
IL (1) IL58087A (xx)
IN (1) IN153099B (xx)
MX (1) MX6521E (xx)
NO (1) NO152445C (xx)
NZ (1) NZ191483A (xx)
PH (1) PH16315A (xx)
PL (2) PL124515B1 (xx)
PT (1) PT70180A (xx)
RO (1) RO77565A (xx)
YU (1) YU41884B (xx)
ZA (1) ZA793973B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340726A (en) * 1980-03-14 1982-07-20 Newport Pharmaceuticals International, Inc. Esters
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
US5147636A (en) * 1982-11-09 1992-09-15 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives and interferons
US4849411A (en) * 1982-11-09 1989-07-18 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
HUT36464A (en) * 1983-05-24 1985-09-30 Newport Pharmaceuticals Process for producing erythro-4-amino-3-/2-hydroxy-3-alkyl/-imidazol-5-carboxamide
IT1215339B (it) * 1987-01-14 1990-02-08 Co Pharma Corp Srl Procedimento per la preparazione di 9-(idrossialchil)-ipoxantine
US5091432A (en) * 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
NZ291592A (en) 1994-07-25 2001-03-30 Michel P Rathbone Use of carbon monoxide dependent guanylyl cyclase modulating purine derivative for treating neurological diseases
WO1997028803A1 (en) * 1996-02-12 1997-08-14 Cypros Pharmaceutical Corporation Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
US6297226B1 (en) 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US6849735B1 (en) * 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
ES2385931T3 (es) 2000-07-07 2012-08-03 Spectrum Pharmaceuticals, Inc. MÉTODOS PARA EL TRATAMIENTO DE NEUROPATíA PERIFÉRICA INDUCIDA POR UNA ENFERMEDAD Y AFECCIONES RELACIONADAS.
US6759427B2 (en) 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
CA2540598C (en) * 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7585850B2 (en) * 2004-02-10 2009-09-08 Adenobio N.V. Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3215696A (en) * 1965-11-02 Substituted adenines -and preparation thereof
US3728450A (en) * 1969-08-28 1973-04-17 Newport Pharmaceuticals Inosine derivatives
BE755361A (fr) * 1969-08-28 1971-03-01 Newport Pharmaceuticals Derives de l'inosine
US3857940A (en) * 1971-05-21 1974-12-31 Newport Pharmaceuticals Inosine derivatives
US3836656A (en) * 1972-02-07 1974-09-17 Sandoz Ag Substituted purines as hypolipidemics
US3862189A (en) * 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
US4060616A (en) * 1976-03-01 1977-11-29 Burroughs Wellcome Co. Purine derivatives with repeating unit
YU96177A (en) * 1976-04-24 1982-08-31 Wuelfing Johann A Process for obtaining adenine derivatives

Also Published As

Publication number Publication date
KR840000552A (ko) 1984-02-25
JPS5547683A (en) 1980-04-04
EP0009154B1 (en) 1982-12-08
AU527851B2 (en) 1983-03-24
ZA793973B (en) 1980-09-24
FI68234C (fi) 1985-08-12
DE2964211D1 (en) 1983-01-13
IL58087A (en) 1983-03-31
IE791753L (en) 1980-03-15
YU41884B (en) 1988-02-29
IE48827B1 (en) 1985-05-29
AU5055779A (en) 1980-03-20
DK149857B (da) 1986-10-13
CS251060B2 (en) 1987-06-11
JPH031309B2 (xx) 1991-01-10
HU182544B (en) 1984-02-28
YU224579A (en) 1983-12-31
NO152445C (no) 1985-10-02
PH16315A (en) 1983-09-05
MX6521E (es) 1985-06-27
DK385679A (da) 1980-03-16
RO77565A (ro) 1981-11-04
PL218317A1 (xx) 1980-06-16
NO152445B (no) 1985-06-24
IN153099B (xx) 1984-06-02
FI68234B (fi) 1985-04-30
ES484167A1 (es) 1980-09-01
NZ191483A (en) 1983-06-14
PL119685B1 (en) 1982-01-30
PL124515B1 (en) 1983-01-31
FI792849A (fi) 1980-03-16
PT70180A (en) 1979-10-01
EP0009154A1 (en) 1980-04-02
DK149857C (da) 1987-03-02
GR74076B (xx) 1984-06-06
NO792792L (no) 1980-03-18
CA1122217A (en) 1982-04-20
US4221909A (en) 1980-09-09
ATE1949T1 (de) 1982-12-15

Similar Documents

Publication Publication Date Title
DD146049A5 (de) Verfahren zur herstellung von komplexverbindungen von 9-hydroxyalkyl-purinen
US4221794A (en) Method of imparting immunomodulating and antiviral activity
DD146050A5 (de) Verfahren zur herstellung von 9-hydroxyalkylpurinen
DE3891468C2 (de) Äthylester der 6-Brom-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiomethylindol-3-karbonsäure des monohydrat-hydrogenchlorids, Verfahren zu seiner Herstellung und Arzneipräparat mit antiviraler, interferoninduzierender und immunomodulierender Wirkung auf seiner Grundlage
DE69732413T2 (de) Verfahren zur synthese chemischer verbindungen mit pde-iv-hemmender wirkung
CH626363A5 (xx)
DE3406275A1 (de) Neue adenosinrezeptoren-antagonisten
DE2120495A1 (de) Neue Trialkoxychinazolin-Verbindungen und Verfahren zu ihrer Herstellung
DE2056327A1 (de) Aminopunn Derivate
DD156813A5 (de) Verfahren zur herstellung von estern von 9-hydroxyalkylpurinen
DE69319590T2 (de) Melamine derivate zur verwendung in der behandlung von krebs
DE3873207T2 (de) Antivirale therapie gegen hepatitis b mit 2',3'-didesoxynucleosiden.
DD284026A5 (de) Verfahren zur herstellung von estern
DE2836373C2 (de) Purinderivate
DE2708826A1 (de) Substituierte 8-azapurine und verfahren zu ihrer herstellung
DE2135543A1 (de) Benzthiazolderivate enthaltende arzneimittel
DE3218792A1 (de) Isoprenylaminderivate und deren saeureadditionssalze
AT397802B (de) Pyrimidinderivate
DE2618223C2 (xx)
DE2038035A1 (de) 2-Amino-pyrido eckige Klammer auf 2,3-d eckige Klammer zu pyrimidin-4(3H)on-Derivate
DE2513930A1 (de) 1-oxo-1h-6-hydroxypyrimido eckige klammer auf 1,2-a eckige klammer zu chinolin-2-carbonsaeuren und deren derivate
DE2537294C3 (de) S-Inosyl-L-cystein und Verfahren zu seiner Herstellung
DE2403786A1 (de) Neue derivate der cumarine
DE2522047A1 (de) Pharmazeutisches mittel zum induzieren von interferon
DE2806199A1 (de) Aminopyrimidinverbindungen, verfahren zu ihrer herstellung und arzneimittel

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee